



Bicycle Therapeutics is named winner of Fierce Innovation Award

December 21, 2016

Bicycle Drug Conjugates® Take Top Prize for Drug Delivery Technology

CAMBRIDGE, U.K. and CAMBRIDGE, MASS. – DECEMBER 21, 2016 – Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (*Bicycle®*) product platform, announced today that it has been selected by a panel of industry experts as the winner of the best Drug Delivery Technology category in the Fierce Innovation Awards for Life Sciences 2016.

"We are honored to be chosen by Fierce as the top innovator in drug delivery technology, a distinction that reflects the broad potential of our novel product platform to create new medicines to treat oncology and other serious diseases," said Kevin Lee, Ph.D., Bicycle's Chief Executive Officer. "This award is further validation of the progress we have made in advancing the Bicycle platform and a tribute to the talented drug discovery and development team we have in place to drive our efforts forward."

Bicycle Therapeutics is developing a new class of small molecular weight drugs known as *Bicycles®* for oncology and other diseases. *Bicycles®* combine properties of several therapeutic entities in a single modality, exhibiting the affinity and target specificity typically associated with antibodies, but in a small molecule format that enables rapid tissue penetration and flexible routes of administration. Because of their peptidic nature, *Bicycles®* are cleared via the kidney, sparing liver and gastrointestinal toxicity often seen with other drug modalities. *Bicycles* can be used as stand-alone therapeutics or as *Bicycle Drug Conjugates®* delivering other molecular cargos such as toxins, small molecules or nucleic acids to tissue or tumour specific antigens. The company's lead molecule, BT1718, is a *Bicycle Drug Conjugate®* (BDC) expected to enter the clinic in 2017 to treat solid tumours.

About the Fierce Innovation Awards

Created by the publisher of *FierceBiotech* and *FiercePharma*, the Fierce Innovation Awards: Life Sciences Edition showcase outstanding innovation that is driving improvements and transforming the industry. Chosen by an expert panel of judges, awards are given to those advances deemed to have the potential to make the greatest impact for biotech and pharma companies.

About Bicycle Therapeutics

Bicycle Therapeutics is developing a new class of medicines to treat oncology and other debilitating diseases based on its proprietary bicyclic peptide (*Bicycle®*) product platform. *Bicycles®* exhibit an affinity and exquisite target specificity usually associated with antibodies, whilst a low molecular weight delivers rapid and deep tissue penetration enabling more efficient tumour targeting. Their peptidic nature provides a "tuneable" pharmacokinetic half-life and a renal route of clearance, avoiding the liver and gastrointestinal tract toxicities often seen with other drug modalities. Bicycle Therapeutics is rapidly advancing towards the clinic with its lead molecule, BT1718 and is collaborating in oncology and other areas to realise the full potential of the Bicycle Therapeutics Limited. Bicycle Therapeutics' unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis. Bicycle Therapeutics is headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge, Massachusetts. For more information, visit www.bicycletherapeutics.com.

Contacts:

Ten Bridge Communications (U.S.)
Sarah Sutton
Sarah@tenbridgecommunications.com
+1-857-242-1619

Consilium Strategic Communications (EU)
Mary-Jane Elliott / Chris Gardner / Ivar Milligan
Bicycle@consilium-comms.com
+44 20 3709 5700